SCHEMBL9924222

SCHEMBL9924222

O=C(/N=C(/Nc1cc(F)cc(Cl)c1)N[C@H]1CC[C@H](O)CC1)c1cccc(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.44
SLC6A9 P48067 1/20 0.43
SLC6A5 Q9Y345 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
GRM5 P41594 6/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 1/20 0.40
EPHX1 P07099 1/20 0.40
TSHR P16473 1/20 0.40
EPHX2 P34913 1/20 0.40
CRHR1 P34998 1/20 0.39
GRM4 Q14833 1/20 0.39
IDO1 P14902 1/20 0.39
ACKR3 P25106 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17206624 1.00 CYP2D6 (0.44) CYP2D6SLC6A9SLC6A5L3MBTL1RAB9A
SCHEMBL9924131 0.90 NPC1 (0.50) CYP2D6L3MBTL1RAB9ANPC1GRM5
SCHEMBL17206620 0.89 GRM4 (0.39) CYP2D6SLC6A9SLC6A5RAB9ANPC1
SCHEMBL9924215 0.89 SLC6A9 (0.41) CYP2D6SLC6A9SLC6A5RAB9ANPC1
SCHEMBL9924260 0.85 MEN1 (0.46) CYP2D6L3MBTL1RAB9ANPC1MEN1
SCHEMBL9924261 0.84 TRPV1 (0.42) CYP2D6SLC6A9MEN1KMT2AEPHX2
SCHEMBL9924333 0.84 NPC1 (0.44) L3MBTL1RAB9ANPC1GRM5MEN1
SCHEMBL9924130 0.82 DCUN1D1 (0.52) CYP2D6MEN1KMT2ALMNAEPHX2
SCHEMBL9924214 0.82 MEN1 (0.49) CYP2D6L3MBTL1RAB9ANPC1MEN1
SCHEMBL9924457 0.82 NPC1 (0.43) RAB9ANPC1GRM5MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed